Amid complaints about unilateral drug company restrictions on the 340B drug pricing program and mounting pressure from industry-backed advocates for even more 340B changes to favor drugmakers, a bipartisan group of six U.S. senators have taken a proactive step by asking for ideas to ensure “stability” for 340B. This move came in the form of a request for information (RFI) … [Read more...]
Drug Industry Report on 340B Attempts a Diversion from Unlawful Manufacturer Actions
October 14, 2020— A new report from the drug industry consultant Berkeley Research Group (BRG) takes aim at community-based pharmacies in the 340B drug pricing program. The report implies, without evidence, that for-profit pharmacy chains are making excessive profits on these arrangements. It ignores the fact that these partnerships provide critical funding for safety-net and … [Read more...]
Outcry Intensifies Over Pharma Moves Against 340B
September 10, 2020— Five major pharmaceutical companies are flouting the 340B drug pricing program statute, and others appear poised to follow suit. But a vocal group of safety-net providers and national organizations are calling on the federal government to use its authority to put a stop to those actions before patients are harmed. Beginning in late June, the drug makers … [Read more...]
No Fooling: Drug Maker 340B Price Transparency Has Improved
April 1, 2020– The first of April is an opportunity for people to play good-natured pranks on their family and friends. But this year it also gives hospitals participating in the 340B drug pricing program a chance to reflect on something that is definitely not a joke – drug manufacturer pricing transparency has improved because of a federal website that went live a year ago … [Read more...]
New Report Misses the Mark on 340B Program
November 19, 2019– The latest report from AIR340B, a group financed and backed by the pharmaceutical industry, again misrepresents the 340B drug pricing program and its long history of helping hospitals stretch scarce resources to better serve low-income and rural patients. As part of its efforts to sharply restrict 340B, the group misleads policymakers and the public by … [Read more...]
Drug companies answer scrutiny with more lobbying dollars
May 2, 2019— With its pricing practices under a congressional microscope, the pharmaceutical industry’s top trade group spent nearly $10 million on lobbying expenditures in the first three months of this year. That figure is on top of additional millions spent by some of the individual companies that have received the most attention recently in the drug pricing … [Read more...]
Judge Orders Dec. 21 Hearing in Suit to Block Huge Cuts to 340B Hospitals
November 28, 2017—A federal district judge has scheduled a Dec. 21 hearing in the lawsuit seeking to stop drastic Medicare Part B drug reimbursement cuts for many 340B hospitals from taking effect on Jan. 1. … [Read more...]